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Abstract  
Purpose of review: The incidence of pulmonary infections has declined dramatically with 
improved access to antiretroviral therapy (ART) and co-trimoxazole prophylaxis, but 
chronic lung disease (CLD) is an increasingly recognized but poorly understood complication 
in adolescents with perinatally-acquired HIV.  
Recent findings: There is a high prevalence of chronic respiratory symptoms, abnormal 
spirometry and chest radiographic abnormalities among HIV-infected adolescents in sub-
Saharan Africa, where 90% of the world’s HIV-infected children live. The incidence of 
lymphocytic interstitial pneumonitis, the most common cause of CLD in the pre-ART era, has 
declined with increased ART access. Small airways disease, particularly constrictive 
obliterative bronchiolitis and bronchiectasis are emerging as leading causes of CLD among 
HIV-infected adolescents in low- and middle-income countries. Asthma may be more 
common in high-income settings. Likely risk factors for CLD include recurrent pulmonary 
infections, air pollution, HIV-related immune dysfunction and untreated HIV infection, 
particularly during critical stages of lung development. 
Summary: Globally, the importance of HIV-associated CLD as a cause of morbidity and 
mortality is increasing, especially as survival has improved dramatically with ART and 
growing numbers of children living with HIV enter adolescence. Further research is urgently 
needed to elucidate the natural history and pathogenesis of CLD, and to determine optimal 
screening, diagnostic and treatment strategies. 
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Introduction 
Of the estimated 3.4 million children living with HIV globally, 90% live in sub-Saharan Africa 
[1]. Although the number of children born with HIV is declining due to scale-up of prevention 
of mother-to-child transmission (PMTCT) programmes, growing numbers of HIV-infected 
children are surviving to adolescence due to the widespread roll-out of antiretroviral 
therapy (ART) [2]. In addition, approximately one-third of HIV-infected infants survive to 
adolescence in the absence of ART, and children infected a decade ago when PMTCT 
programmes and early infant diagnosis were not available, are now presenting to health 
services in large numbers for the first time in older childhood and adolescence [3]. 
Consequently, the burden of paediatric HIV is shifting toward adolescents [2].  
 
While the incidence of acute pulmonary infections in HIV is declining due to the use of co-
trimoxazole prophylaxis and ART [4-6,7**], chronic lung disease (CLD) is emerging as an 
important, but incompletely understood, complication among older children and 
adolescents living with HIV [8*]. In particular, adolescents with delayed diagnosis of 
perinatally-acquired HIV have a disproportionately high burden of chronic respiratory 
disease [8*,9*,10*,11*]. We review the spectrum of and risk factors for HIV-associated CLD 
among adolescents living with HIV, as well as considerations in diagnosis and management.  
 
Spectrum of chronic lung disease 
Recent studies from sub-Saharan Africa highlight a substantial burden of chronic respiratory 
symptoms and poor lung function among HIV-infected adolescents. Over half of older 
children and adolescents reported at least one chronic respiratory symptom in recent 
studies from Zimbabwe, Malawi and Kenya [8*,10*,11*,12*,13*,14*]. Chronic cough and 
sputum production were reported by 21-60% and breathlessness by 12-18%, but wheezing 
was uncommon [8*,10*,11*,12*,13*,14*,15*]. The prevalence of tachypnoea is difficult to 
quantify as definitions vary between studies, but elevated respiratory rates are common 
[8*,9*,10*,11*, 15*]. Hypoxia after sub-maximal exercise was a striking finding among 12-
38% [10*,11*,12*,13*,15*,16*]. One-third of adolescents had abnormal spirometry: forced 
expiratory volume in one second (FEV1) and forced vital capacity (FVC) were lower among 
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those with HIV, compared to age-, sex-, race- and height-adjusted predicted values, and 
compared to HIV-uninfected controls [8*,15*,17]. While some studies documented a 
substantial prevalence of airflow obstruction [10*,11*,12*], others reported a prominence 
of a restricted pattern [11*,13*,14*]; there was little reversibility with bronchodilators. One 
study additionally measured lung volumes, compliance and transfer factor for carbon 
monoxide, finding that each was lower among HIV-infected compared to uninfected 
participants [18**]. A recent study from the USA also showed a high prevalence of poorly 
reversible airflow obstruction [19*]. Taken together, these studies suggest that CLD may be 
more common among HIV-infected adolescents than previously appreciated (Table 1). 
 
The term CLD comprises a spectrum of lung diseases whose prevalence varies between 
LMICs and high-income countries. The pathogenesis is multifactorial, but HIV-related 
immune dysfunction is likely important.    
 
Bronchiectasis 
Bronchiectasis is a well-recognized and irreversible cause of CLD among HIV-infected 
children and adolescents [20]. The bronchial architecture is distorted with bronchial 
diameter enlargement relative to the adjacent pulmonary artery, which appears as a “ring” 
or “tramline” pattern on chest radiography [21*,22*]. A study from the USA in the pre-ART 
era reported that 6% of 749 HIV-infected children without pre-existing lung disease 
developed radiographically or histologically determined bronchiectasis during an average of 
six years of follow-up [23]. In contrast, in two recent studies conducted in Zimbabwe and 
Malawi among older children and adolescents with perinatally-acquired HIV, one-half had 
chest radiographic features consistent with bronchiectasis [8*,11*]. Two-thirds of children 
in the African studies were on ART for at least a median duration of 20 months and had 
median CD4 >350 cells/µL. The lower prevalence of bronchiectasis in the USA study despite 
unavailability of ART was probably due to earlier engagement with healthcare services, 
prompt treatment of infections and greater attention to maintaining adequate nutrition.  
 
Multiple insults can result in bronchiectasis, including recurrent pulmonary infections, 
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chronic aspiration, and congenital or acquired immunodeficiency syndromes 
[17,20,21*,22*,23,24]. HIV is associated with an increased risk of tuberculosis, and recurrent 
viral and bacterial pulmonary infections [7**,17,23,24,25*,26]. However, some data suggest 
that HIV predisposes to bronchiectasis independently of infection, likely due to HIV-
mediated defects in innate immunity and accompanying airway neutrophilic inflammation 
[17,21*,22*,27]. Bronchiectasis in adolescents can also occur as a late complication of 
lymphocytic interstitial pneumonitis (LIP) [24]. Bronchiectasis accounts for a substantial 
proportion of chronic respiratory symptoms, reduced quality of life and risk of premature 
death [22*]. 
 
Constrictive obliterative bronchiolitis 
In 2012, Ferrand and colleagues first reported a high prevalence of chronic respiratory 
symptoms among perinatally HIV-infected children diagnosed in adolescence, nearly three-
quarters of whom were taking ART [8*]. This was the first study to perform high-resolution 
computed tomography (HRCT) in this context. Among the 56 adolescents with chronic 
respiratory symptoms, the most common HRCT finding was a mosaic pattern of decreased 
attenuation in 55% (Figure 1). Decreased attenuation was associated with reduced FEV1 and 
chronic cough [16*]. Together with hypoxia and irreversible airflow obstruction, these 
findings are consistent with constrictive obliterative bronchiolitis (cOB). This was the first 
study to demonstrate cOB as a major cause of CLD. To our knowledge, there are no reports 
of HIV-associated cOB among adolescents in high-income settings, although the findings by 
Shearer and colleagues could partly be explained by small airways disease [19*]. Due to the 
cross-sectional nature of these data, however, it is not possible to determine whether 
findings reflect abnormalities persisting from insults during childhood or recent-onset 
disease [28*].  
 
The pathogenesis and natural history of cOB among HIV-infected adolescents is not well 
understood. This rare, usually progressive, and fibrotic and inflammatory condition involves 
the small airways involved in gas exchange, namely the terminal and respiratory 
bronchioles, but spares the lung parenchyma [29]. These bronchiolar lesions are patchy and 
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may be missed on transbronchial biopsy. Clinically, cOB presents with progressive dyspnea 
and cough over weeks to months, and hypoxia may be detected in severe cases.  The 
predominant diagnostic features of cOB are poorly reversible airflow obstruction, a mosaic 
pattern of decreased attenuation on HRCT, and air trapping on pulmonary function testing 
and/or expiratory HRCT images (Figure 1). Chest radiographs are often normal, or may 
demonstrate only hyperinflation, until cOB is advanced. It has been mainly described in lung 
and stem cell transplant patients with chronic rejection and graft-versus-host disease, and 
as a sequela of community-acquired respiratory viral infections (i.e., influenza, 
parainfluenza, adenovirus, respiratory syncytial virus) and cytomegalovirus infection. It is 
very rarely reported among HIV-uninfected children after community-acquired respiratory 
viral infections.  The high incidence of viral infections among children and adolescents with 
HIV may play an important role in development of cOB, particularly in those with delayed 
diagnosis and treatment of HIV [25*]. Additionally, decreased attenuation was strongly 
correlated with bronchiectasis and bronchial wall thickening and dilatation on HRCT [8*], 
suggesting a continuum of pathological processes that links small and large airways 
involvement. Although disease course and prognosis of cOB are not known among HIV-
infected adolescents, in other populations, cOB responds poorly to therapy and is associated 
with a high risk of mortality over months to years.  
 
Lymphocytic interstitial pneumonitis 
Globally, LIP was the most common cause of CLD among HIV-infected children during the 
pre-ART era [20,30,31]. It is generally responsive to ART, although severe LIP may require 
adjunct corticosteroid therapy. The overall incidence of LIP has declined dramatically with 
the scale-up of ART, and in recent studies, LIP appears to be uncommon among older 
children and adolescents with HIV. A review of chest radiographic findings in HIV-infected 
children and adolescents reported that pulmonary tuberculosis and LIP accounted for 70% 
and 15% of cases, respectively [32*]. However, three-quarters of included studies were 
conducted during the pre- and early ART era or in ART-naïve individuals. In two recent 
studies of generally ART-experienced HIV-infected adolescents from Zimbabwe, HRCT was 
strongly suggestive of LIP in <3% [8*,16*].  
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Asthma 
Conflicting data suggest that asthma risk may be higher among HIV-infected compared with 
HIV-uninfected children and adolescents, especially in high-income settings [33,34]. Among 
1201 HIV-infected adolescents living in the USA, of whom 87% were perinatally-infected and 
85% were taking ART, asthma was a common comorbid condition with an incidence of 
1.2/100 person-years [35**]. In a study of Thai children with perinatally-acquired HIV, early 
initiation of ART was associated with higher CD4, and the prevalence of asthma (27%) 
exceeded that of uninfected Thai children (18%) [36*]. Asthma tended to be more common 
among individuals with preserved immune function, and may be linked to immune 
reconstitution [36*,37-39]. However, the prevalence may have been overestimated in these 
studies, as diagnosis was based on self-report, diagnostic codes or prescription of asthma-
related medications. In a study that performed spirometry in 216 perinatally HIV-infected 
adolescents in the USA, only 30% of those with airflow obstruction had bronchodilator 
reversibility (overall, 9% of those with interpretable spirometry) [19*]. In Zimbabwe, 3-5% 
of older children and adolescents with perinatally-acquired HIV reported a history of asthma 
[13*,15*], similar to the prevalence estimated in the general African paediatric population 
[40]. Reversibility with bronchodilators was uncommon in African studies reporting airflow 
obstruction among HIV-infected adolescents, with the exception of one South African study 
in which 15% had reversibility [10*,11*,12*,13*,18**]. While asthma prevalence may be 
underestimated in LMICs where few systematic surveys have been completed, it is plausible 
that incidence is low, but could increase with industrialization, as observed in South Africa.  
 
Pulmonary hypertension 
HIV-related pulmonary arterial hypertension is rare with an estimated prevalence of 0.5% 
among adults in high-income countries; however, small studies from sub-Saharan Africa 
suggest a prevalence of 5-13% [41,42*]. Pulmonary hypertension is rarely described in HIV-
infected children and adolescents [43]. A study in Zimbabwe reported that 4% of perinatally 
HIV-infected adolescents had elevated estimated pulmonary artery systolic pressure (>30 
mmHg) on echocardiography [44]. Overall, 30% had right ventricular dilatation, and 24% 
had concurrent impaired left ventricular function. In another study, 28% of HIV-infected 
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children and adolescents had right ventricular dilatation, and two-thirds had concomitant 
left heart abnormalities [45*]. Pulmonary hypertension prevalence, however, remains 
uncertain as echocardiography may over- or underestimate prevalence [46], and use of 
pulmonary angiography, the diagnostic gold standard, is limited in LMICs. HIV-related 
pulmonary hypertension in adolescents may be multifactorial as a sequela of HIV itself or 
secondary to HIV-associated immune dysfunction and/or cardiopulmonary disease [42,47]. 
 
Risk factors for HIV-associated chronic lung disease among adolescents 
The burden of CLD among HIV-infected adolescents appears to be greater in LMICs. This may 
be due to a higher prevalence of risk factors, including pulmonary infections, household air 
pollution, malnutrition and stunting [1,7**,48]. Additionally, in contrast with high-income 
settings where the majority of HIV-infected children initiate ART in infancy, a substantial 
proportion of children are diagnosed with HIV and initiate ART in later childhood. Among 
adolescents with delayed diagnosis of perinatally-acquired HIV in sub-Saharan Africa, older 
age and low FEV1 and FVC z-scores appear to be associated [9*,11*,13*,15*]. This might 
reflect accumulation of insults over time and survivor bias. Multiple risk factors may interact 
to predispose to CLD (Figure 2).  
 
Pulmonary infections 
Pulmonary pathogens can trigger local inflammation, resulting in scarring and destruction 
of lung tissue [49]. Pulmonary infections, including Pneumocystis jirovecii pneumonia (PCP), 
bacterial pneumonia, and tuberculosis are associated with permanent lung function 
abnormalities among HIV-infected adults [50,51]. Recurrent and severe pulmonary 
infections early in life are also associated with impaired lung function, and these early 
impairments may track through later life [52*,53]. Increasing availability of ART and co-
trimoxazole have resulted in a decline in the incidence of bacterial pneumonia, pulmonary 
tuberculosis, and PCP [54,55]. In LMICs, pulmonary infections remain common despite 
decreases in incidence, and risk of pulmonary infections is particularly high among those 
with delayed diagnosis and treatment of HIV [26,56*]. 
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HIV infection, systemic immune activation and chronic inflammation 
HIV infection is associated with systemic immune activation and chronic inflammation [57-
59]. This is driven by translocation of microbial products, including lipopolysaccharide, into 
the systemic circulation through a gastrointestinal mucosa made “leaky” as a result of HIV 
HIV-mediated inflammation of gut lymphoid tissue [59-61]. The resultant immune 
dysregulation is associated with end-organ damage [58,62-64], and may be important 
mechanistically in CLD development. HIV itself is an independent risk factor for COPD among 
adults [6,65,66]. Preliminary data suggest that HIV is also independently associated with 
CLD in children and adolescents [12*,15*,18**]. Infancy and early childhood are critical 
periods for organ and immune system development. HIV-mediated immune dysregulation 
may place children at high risk of lung damage, particularly those with untreated HIV, and 
recurrent pulmonary infections may further accelerate lung function decline. These 
pathophysiological mechanisms may partly explain why adolescents in LMICs, where HIV 
diagnosis and ART initiation are often delayed [67*,68], have a higher prevalence of CLD. 
 
While ART reduces markers of inflammation, residual systemic immune activation and 
chronic inflammation persist [61,69]. The impact of ART on the course of CLD remains 
unclear. An African study reported a lower prevalence of cough, breathlessness and hypoxia, 
but no difference in lung function among HIV-infected adolescents who had received ART for 
a median of five years compared to an age-matched group of ART-naïve adolescents [14*]. 
Among HIV-infected Kenyan adolescents and adults, perinatally-acquired HIV and nadir CD4 
<200 cells/µL were associated with airflow obstruction despite near universal ART use 
[12*]. Additionally, in Zimbabwe and South Africa, adolescents with HIV had significantly 
decreased FEV1 and FVC z-scores, lung volumes, and compliance compared to uninfected 
peers, despite a greater than six-year median duration of ART use [15*,18**].  
 
Tobacco smoke and air pollution  
Exposure to tobacco smoke, both prenatally and during infancy, is associated with impaired 
lung function in one year olds [52*]. Cigarette smoking is a recognized risk factor for chronic 
obstructive pulmonary disease (COPD) and lung function decline among adults. Levels of 
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cigarette smoking are increasing among adolescents, particularly in LMICs [70]. Therefore, 
tobacco smoke exposure will likely become an increasingly important contributor to 
development of CLD. 
 
Exposure to household air pollution during early life has been associated with mortality and 
pulmonary infections, which in turn may impair lung function [48,71*,72]. Strong evidence 
also supports the association between household air pollution and CLD, including COPD in 
adults and wheezing in children [48]. To date, no studies have demonstrated a link between 
household air pollution and CLD among HIV-infected adolescents, likely due to confounding 
by other exposures and difficulties in measuring exposures. 
 
Malnutrition and stunted growth 
Both malnutrition and stunting are common among children and adolescents living with HIV 
in LMICs, with prevalence estimated as high as 42% and 73%, respectively [10*,73-76]. 
Malnutrition during the first year of life is associated with decreased lung function at one 
year of age [52*]. In a Kenyan study, stunting was associated with tachypnoea among HIV-
infected adolescents [9*]. Stunting is a marker of delayed somatic growth; therefore, stunted 
children are likely to have smaller lungs [77*], which may subsequently predispose to CLD. 
 
Assessment and management of chronic lung disease  
Awareness of the burden and spectrum of HIV-associated CLD is limited. Several studies 
have proposed criteria for defining CLD in children and adolescents [8*,11*,56*], but a 
sensitive and specific clinical algorithm has not been established. Chest radiographic 
abnormalities are nonspecific for many CLD subtypes and may be visible only in late stages 
of disease. Availability of diagnostic modalities such as spirometry and HRCT is limited in 
LMICs.  
 
In the absence of appropriate diagnostics, chronic respiratory symptoms are frequently 
empirically treated with repeated courses of antibiotics and anti-tuberculosis therapy in 
high HIV prevalence settings where tuberculosis is common [8*,15*,17]. The pathogenesis 
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of CLD is poorly understood, and there are no specific management guidelines. However, 
prevention of pulmonary infections by ensuring routine vaccinations, early ART initiation 
and continued co-trimoxazole use may mitigate the burden of CLD among HIV-infected 
adolescents [78].  
 
Future directions 
Prospective studies to understand the natural history, pathology and pathogenesis of CLD in 
HIV-infected adolescents are needed. Standardization of the definition of CLD and of data 
collection/measurement will allow for comparability across studies and merging of data to 
achieve greater power to detect associations. Additionally, locally-derived references for 
defining abnormal lung function in children are needed in LMICs. The 2016 WHO HIV 
guidelines recommend treatment of all individuals regardless of age or immune status, 
which should facilitate earlier ART initiation. However, once established, CLD does not 
appear to be completely reversed by ART. Screening algorithms for CLD for children and 
adolescents need to be developed, and interventions such as long-term macrolide therapy, 
prophylactic antibiotics, pulmonary rehabilitation and tobacco smoke avoidance/cessation 
programmes require evaluation. 
 
Conclusion 
Recent studies demonstrate a high burden of CLD and its manifestations among HIV-infected 
older children and adolescents, particularly in LMICs. CLD represents a spectrum of 
conditions with overlapping risk factors and pathogenic mechanisms. As greater numbers of 
HIV-infected children survive to adolescence, the prevalence of CLD in this age-group is 
likely to increase. Further research is urgently needed to develop optimal diagnostic and 
therapeutic strategies so as to avoid compromising the substantial gains in mortality 
accomplished with ART among HIV-infected children.  
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Key points  
1. Chronic lung disease is increasingly recognized as a complication among older children 
and adolescents with perinatally-acquired HIV.  
2. The burden of chronic lung disease disproportionally affects those living in LMICs. 
3. The most common causes of chronic lung disease appear to be large and small airways 
disease, which may be poorly responsive to antiretroviral therapy once established  
4. The prevalence and incidence of lymphocytic interstitial pneumoniitis appear to have 
decreased dramatically with the global scale-up of antiretroviral therapy.  
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Figure 1. Representative lung high-resolution computed tomography findings in 
adolescents with perinatally-acquired HIV. (Copied from Ferrand, et al. [8*] with 
permission.) 
 
 
 
A, Image section at the level of the carina in a 15-year-old female. There is a clear zone of 
decreased attenuation in the right upper lobe (and, to a lesser extent, the left lung). In 
regions of decreased attenuation there is reduction in the caliber of pulmonary vessels; 
there was no bronchiectasis in this patient. B, Image section in a 19-year-old male through 
the lower zones demonstrating focal areas of decreased attenuation in both lungs (arrows) 
and bronchiectasis in the left lower lobe (arrowheads). 
 
Figure 2: Aetio-pathogenesis of chronic lung disease in HIV-infected adolescents (+ 
Increases risk; - decreases risk) 
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